Dexasone
T-Cell And NK-Cell Neoplasm
Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
39High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04447027CT.gov Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | — | Completed | — | — | — |
NCT03719105CT.gov Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell And NK-Cell Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | National Cancer Institute (NCI) | P1 | CCC · 53 |
| Cyclophosphamide | New York Medical College | P3 | BBB |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Cyclosporin A | Medical College of Wisconsin | P3 | B |
| Equine Atg | Masonic Cancer Center, University of Minnesota | P2 | B |
| Umbilical Cord Blood Mononuclear Cells | Masonic Cancer Center, University of Minnesota | P2 | B |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | B |
| Pembrolizumab | The University of Hong Kong | P2 | CCC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CCC |
+18 more in the T-Cell And NK-Cell Neoplasm cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in T-Cell And NK-Cell Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-t-cell-and-nk-cell-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →